Universal Time: 03:56  |  Local Time: 03:56 (0h GMT)
Select your timezone:



Room: E-Poster Hall

P-11.52 Kidney transplantation from HBsAg+ living donors to HBsAg- recipients: Clinical outcomes at a high-volume center in China

Xianding Wang, People's Republic of China

West China Hospital


Kidney transplantation from HBsAg+ living donors to HBsAg- recipients: Clinical outcomes at a high-volume center in China

Xianding Wang1, Jinpeng Liu1, Tao Lin1.

1Urology, West China Hospital, Sichuan University, Chengdu, People's Republic of China

Background: Data on kidney transplantation (KTx) from hepatitis B surface antigen (HBsAg)+ donors to HBsAg- recipients [D(HBsAg+)/R(HBsAg-)] are limited. We aimed to report the outcomes of D(HBsAg+)/R(HBsAg-) KTx in recipients with or without hepatitis B surface antibody (HBsAb).
Methods: Eighty-three D(HBsAg+)/R(HBsAg-) living KTx cases were retrospectively identified. The 384 cases of KTx from hepatitis B core antibody (HBcAb)+ living donors to HBcAb- recipients [D(HBcAb+)/R(HBcAb-)] were used as the control group. Primary endpoint was post-transplant HBsAg -→+.
Results: Before KTx, 24 donors (28.9%) in the D(HBsAg+)/R(HBsAg-) group were hepatitis B virus (HBV) DNA+, and 20 recipients were HBsAb-. All eighty-three D(HBsAg+)/R(HBsAg-) recipients received HBV prophylaxis, while no D(HBcAb+)/R(HBcAb-) recipients received prophylaxis. After a median follow-up of 36 months (range 6-106) and 36 months (range 4-107) for the D(HBsAg+)/R(HBsAg-) and D(HBcAb+)/R(HBcAb-) groups, respectively, 2/83 (2.41%) D(HBsAg+)/R(HBsAg-) recipients and 1/384 (0.26%) D(HBcAb+)/R(HBcAb-) became HBsAg+, accompanied with HBV DNA+ (P=0.083). The three recipients with HBsAg-→+ were exclusively HBsAb-/HBcAb- before KTx. Recipient deaths were more frequent in the D(HBsAg+)/R(HBsAg-) group (6.02% vs. 1.04%, P=0.011), while liver and graft function, rejection, infection, and graft loss were not significantly different. In univariate analyses, pre-transplant HBsAb-/HBcAb- combination in the D(HBsAg+)/R(HBsAg-) recipients carried a significantly higher risk of HBsAg-→+, HBV DNA-→+, and death.
Conclusions: Living D(HBsAg+)/R(HBsAg-) KTx in HBsAb+ recipients provides excellent graft and patient survivals without HBV transmission. HBV transmission risks should be more balanced with respect to benefits of D(HBsAg+)/R(HBsAg-) KTx in HBsAb-/HBcAb- candidates.

This work was supported by grants from the National Natural Science Foundation of China [grant number 81870513, 81470980, and 81600584]; Sichuan Science and Technology Program [grant number 2019YJ0133]; the Fundamental Research Funds for the Central Universities [grant number 2017SCU11022]; and 1.3.5 Project for Disciplines of Excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University [grant number 2018HXFH049, ZYJC18004, ZY2016104]. The funders had no role in study design, data collection or analysis, preparation of the manuscript, or the decision to publish..


There are no comments yet...

WebApp Sponsor

© 2021 TTS 2020